Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,557 | 6 | 99.5% |
| Food and Beverage | $14.02 | 1 | 0.5% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Astellas Pharma Global Development | $2,557 | 6 | $0 (2018) |
| Agile Therapeutics, Inc. | $14.02 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $14.02 | 1 | Agile Therapeutics, Inc. ($14.02) |
| 2018 | $518.60 | 4 | Astellas Pharma Global Development ($518.60) |
| 2017 | $2,038 | 2 | Astellas Pharma Global Development ($2,038) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/22/2022 | Agile Therapeutics, Inc. | Twirla (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: Birth Control Contraceptive Patch | ||||||
| 03/15/2018 | Astellas Pharma Global Development | MICAFUNGIN (Drug) | — | In-kind items and services | $140.45 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis • Category: INFECTIOUS DISEASES | ||||||
| 03/15/2018 | Astellas Pharma Global Development | MICAFUNGIN (Drug) | — | In-kind items and services | $140.45 | Research |
| Study: Exposure-Response Analysis of Micafungin in Neonatal Candidiasis Pooled analysis of two clinical trials • Category: INFECTIOUS DISEASES | ||||||
| 03/15/2018 | Astellas Pharma Global Development | MICAFUNGIN (Drug) | — | In-kind items and services | $118.85 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis • Category: INFECTIOUS DISEASES | ||||||
| 03/15/2018 | Astellas Pharma Global Development | MICAFUNGIN (Drug) | — | In-kind items and services | $118.85 | Research |
| Study: A Phase 3 Study of Micafungin versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis Neonates 3 • Category: INFECTIOUS DISEASES | ||||||
| 10/17/2017 | Astellas Pharma Global Development | Micafungin (Drug) | — | In-kind items and services | $634.23 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis • Category: Infectious Diseases | ||||||
| 02/23/2017 | Astellas Pharma Global Development | Mycamine (Drug) | — | In-kind items and services | $1,403.98 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis • Category: Infectious Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | Astellas Pharma Global Development | $2,298 | 4 |
| Exposure-Response Analysis of Micafungin in Neonatal Candidiasis Pooled analysis of two clinical trials | Astellas Pharma Global Development | $140.45 | 1 |
| A Phase 3 Study of Micafungin versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis Neonates 3 | Astellas Pharma Global Development | $118.85 | 1 |
About David Kaufman
David Kaufman is a Pediatrics healthcare provider based in Charlottesville, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1891864401.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Kaufman has received a total of $2,571 in payments from pharmaceutical and medical device companies, with $14.02 received in 2022. These payments were reported across 7 transactions from 2 companies. The most common payment nature is "" ($2,557).
Practice Information
- Specialty Pediatrics
- Other Specialties Neonatal-Perinatal Medicine
- Location Charlottesville, VA
- Active Since 11/07/2006
- Last Updated 08/28/2019
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1891864401
Products in Payments
- Mycamine (Drug) $1,404
- Micafungin (Drug) $634.23
- MICAFUNGIN (Drug) $518.60
- Twirla (Drug) $14.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Charlottesville
Alan Rogol
Pediatrics — Payments: $241,007
Mr. Paul Wisman, M.d, M.D
Pediatrics — Payments: $19,785
Dr. Christina Peroutka, Md, MD
Pediatrics — Payments: $14,075
Colleen Druzgal, M.d, M.D
Pediatrics — Payments: $13,403
Jonathan Black, M.d, M.D
Pediatrics — Payments: $10,611
Kimberly Dunsmore
Pediatrics — Payments: $8,733